Of 16 evaluable patients with response data, 75% had confirmed durable partial responses and 19% experienced stable disease after CRS-207 and chemotherapy, for a 94% rate of disease control . At the time of the presentation, estimated progression-free survival was 7.5 months with one patient on study for more than 19 months, currently receiving maintenance therapy with CRS-207 following the combination treatment.
